Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Multiple sclerosis

Oral laquinimod for MS—bringing the brain into focus

Nature Reviews Neurology volume 9, pages 664–665 (2013)Cite this article

Subjects

Currently approved multiple sclerosis (MS) treatments mainly target the peripheral immune system, thereby reducing relapse rates and MRI markers of inflammation. A recent phase III trial indicates that laquinimod, a new orally active immunomodulator, has a CNS-intrinsic mode of action that is independent of effects on the peripheral immune response.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Effects of laquinimod in patients with multiple sclerosis in the phase III ALLEGRO trial.

References

  1. Brück, W. et al. Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol. http://dx.doi.org/10.1001/jamaneurol.2013.3510.

  2. Comi, G. et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N. Engl. J. Med. 366, 1000–1009 (2012).

    Article  CAS  Google Scholar 

  3. Filippi, M. et al. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J. Neurol. Neurosurg. Psychiatry http://dx.doi.org/10.1136/jnnp-2013-306132.

  4. Brück, W. et al. Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 124, 411–424 (2012).

    Article  Google Scholar 

  5. Jolivel, V. et al. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain 136, 1048–1066 (2013).

    Article  Google Scholar 

  6. Schulze-Topphoff, U. et al. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS ONE 7, e33797 (2012).

    Article  CAS  Google Scholar 

  7. Brück, W. & Zamvil, S. S. Laquinimod, a once-daily oral drug in development for the treatment of relapsing–remitting multiple sclerosis. Expert Rev. Clin. Pharmacol. 5, 245–256 (2012).

    Article  Google Scholar 

  8. Lassmann, H. Pathology and disease mechanisms in different stages of multiple sclerosis. J. Neurol. Sci. 333, 1–4 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Neuropathology, University Medical Centre Göttingen, Georg-August-University, Robert-Koch-Strasse 40, Göttingen, 37075, Germany

    Wolfgang Brück

  2. Department of Neurology, University of Colorado, Anschutz Medical Campus, Aurora, 80045, CO, USA

    Timothy Vollmer

Authors
  1. Wolfgang Brück
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy Vollmer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wolfgang Brück.

Ethics declarations

Competing interests

W. Brück receives research support from Teva Pharmaceutical Industries, Biogen Idec, Genzyme and Novartis. He is a member of the scientific advisory boards of Teva Pharmaceutical Industries, Biogen Idec, Novartis and Genzyme/Sanofi, and serves on speaker's bureaus for Bayer Vital, Biogen Idec, Merck Serono, Teva Pharmaceutical Industries Ltd., Genzyme/Sanofi and Novartis. T. Vollmer has acted as a consultant for Teva Pharmaceutical Industries, Biogen Idec, Xenoport, Krog & Partners, Novartis Pharmaceuticals, Acorda, Mylan Pharmaceuticals, Hoffman-LaRoche. He has received research support from Janssen-Sergeant Pharmaceuticals, Medimmune, Vaccinex, ONO, Teva Neuroscience, Genzyme, Biogen Idec, Avinir, Acorda and Novartis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brück, W., Vollmer, T. Oral laquinimod for MS—bringing the brain into focus. Nat Rev Neurol 9, 664–665 (2013). https://doi.org/10.1038/nrneurol.2013.234

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2013.234

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing